199 related articles for article (PubMed ID: 27956154)
1. Trastuzumab biosimilar shows potential for breast cancer.
Baker H
Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
[No Abstract] [Full Text] [Related]
2. [Biosimilars in oncology. Focus on SB3 studies.].
Del Re M; Del Mastro L
Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
[TBL] [Abstract][Full Text] [Related]
3. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
4. An Important Step Forward for Biosimilars in Cancer Treatment.
Schleicher SM; Seidman AD
JAMA Oncol; 2017 Jul; 3(7):989-990. PubMed ID: 28196209
[No Abstract] [Full Text] [Related]
5. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
6. A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
Apsangikar P; Chaudhry S; Naik M; Deoghare S; Joseph J
Indian J Cancer; 2017; 54(4):664-668. PubMed ID: 30082554
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA
BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
[TBL] [Abstract][Full Text] [Related]
9. SB3 (Ontruzant
Lamb YN
BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
[TBL] [Abstract][Full Text] [Related]
10. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
11. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers.
Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine for HER2-positive breast cancer.
Venkatesan P
Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
[No Abstract] [Full Text] [Related]
13. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.
Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q
Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186
[TBL] [Abstract][Full Text] [Related]
14. Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.
Stebbing J; Baranau Y; Manikhas A; Lee SJ; Thiruchelvam P; Leff D; Esteva FJ
Expert Rev Anticancer Ther; 2018 Jun; 18(6):531-541. PubMed ID: 29580109
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Esteva FJ; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskiy D; Pikiel J; Eniu AE; Li RK; Rusyn AV; Tiangco B; Lee SJ; Lee SY; Yu SY; Stebbing J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):839-847. PubMed ID: 31428820
[TBL] [Abstract][Full Text] [Related]
16. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
17. [Clinical applications of trastuzumab in the management of HER-2-positive breast cancer.].
Del Mastro L; De Laurentiis M
Recenti Prog Med; 2019 Dec; 110(12):594-603. PubMed ID: 31909762
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of CT-P6 in HER2 positive breast cancer.
Fu C; Stebbing J; Esteva FJ
Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
[No Abstract] [Full Text] [Related]
19. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y
Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar.
Goyal P; Iyer J; Adhikary L; Vats B; Kabadi P; Pai H; Ranayhossaini D; Gouda S; Subbarao M; Mehta G; Saha A; Bera A; Sahu A; Kaur M; Singh A; Marwah A; Reddy Moole PK; Smith J; Melarkode R; Ullanat R
Future Med Chem; 2021 Sep; 13(18):1531-1557. PubMed ID: 34289749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
